For what condition is Cayston (aztreonam) specifically indicated?

Cayston, also known as aztreonam, is specifically indicated for the management of patients with cystic fibrosis who are infected with Pseudomonas aeruginosa. This medication is a type of antibiotic that works by targeting bacterial infections in the lungs, which are common in individuals with cystic fibrosis. The unique formulation of Cayston allows it to be inhaled, delivering the medication directly to the site of infection in the lungs, thereby providing effective treatment while minimizing systemic side effects.

In this context, individuals with cystic fibrosis often require specialized treatments to manage chronic lung infections, and aztreonam has been demonstrated to improve respiratory function and reduce the bacterial burden. Its approval for this specific population underscores its importance in the therapeutic options available for cystic fibrosis patients. Understanding the specific indications for each medication is crucial for optimal patient care, particularly in complex conditions such as cystic fibrosis.